Xencor, a biotherapeutics company developing protein and antibody therapeutics, today announced that it raised $6 million in a bridge financing from new investor Novo Nordisk and existing investors including Zen Investments. Pursuant to the bridge financing, Novo Nordisk has committed to invest an additional $6 million in specified future financings.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060711005323&newsLang=en)